Latigo Biotherapeutics (NASDAQ:LTGO) Stock Jumps 5.5% – Still a Buy?

Posted by Francis Steltz on Oct 23rd, 2026

Latigo Biotherapeutics, Inc. (NASDAQ:LTGO – Get Free Report)’s share price shot up 5.5% on Wednesday. The company traded as high as $16.28 and last traded at $16.09. Approximately 12,705 shares traded hands during trading, a decline of 96% from the average session volume of 301,730 shares. The stock had previously closed at $15.25.

Analyst Upgrades and Downgrades

A number of research firms have commented on LTGO. Jefferies Financial Group began coverage on shares of Latigo Biotherapeutics in a research report on Tuesday, September 1st. They issued a “buy” rating and a $50.00 target price for the company. Guggenheim started coverage on shares of Latigo Biotherapeutics in a research note on Tuesday, September 1st. They set a “buy” rating and a $50.00 target price for the company. Wall Street Zen cut Latigo Biotherapeutics from a “hold” rating to a “sell” rating in a report on Saturday, October 17th. The Goldman Sachs Group began coverage on Latigo Biotherapeutics in a research note on Tuesday, September 1st. They issued a “buy” rating and a $73.00 price target on the stock. Finally, Leerink Partners initiated coverage on Latigo Biotherapeutics in a research note on Tuesday, September 1st. They issued an “outperform” rating and a $36.00 price target on the stock. Four investment analysts have rated the stock with a Buy rating. According to MarketBeat, the stock currently has an average rating of “Buy” and an average target price of $52.25.

Get Our Latest Report on LTGO

Latigo Biotherapeutics Trading Up 1.4%

The firm has a 50 day simple moving average of $19.59.

Latigo Biotherapeutics (NASDAQ:LTGO – Get Free Report) last posted its quarterly earnings data on Thursday, September 3rd. The company reported ($27.59) EPS for the quarter.

Insider Buying and Selling at Latigo Biotherapeutics

In related news, Director James B. Tananbaum purchased 140,000 shares of Latigo Biotherapeutics stock in a transaction on Monday, August 10th. The stock was acquired at an average price of $18.00 per share, for a total transaction of $2,520,000.00. Following the completion of the transaction, the director directly owned 2,008,024 shares in the company, valued at $36,144,432. This represents a 7.49% increase in their position. The purchase was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, major shareholder Foresite Capital Management V, acquired 140,000 shares of the firm’s stock in a transaction dated Monday, August 10th. The stock was bought at an average cost of $18.00 per share, for a total transaction of $2,520,000.00. Following the purchase, the insider directly owned 2,008,024 shares of the company’s stock, valued at approximately $36,144,432. This trade represents a 7.49% increase in their ownership of the stock. The SEC filing for this purchase provides additional information.

About Latigo Biotherapeutics

(Get Free Report)

Latigo Biotherapeutics, Inc is a clinical-stage biopharmaceutical company developing non-opioid treatments for pain. The company focuses on therapies designed to selectively target Nav1.8, a sodium channel expressed in peripheral sensory neurons that plays an important role in the transmission of pain signals.

Latigo’s lead product candidate, LTG-001, is an oral, selective Nav1.8 inhibitor being developed for the treatment of acute and chronic pain conditions. By targeting pain signaling outside the central nervous system, the company aims to develop alternatives to opioid medicines and other pain treatments that may carry significant safety or tolerability concerns.